POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation

BRAF inhibitors (BRAFi) have shown remarkable clinical efficacy in the treatment of melanoma with BRAF mutation. Nevertheless, most patients end up with the development of BRAFi resistance, which strongly limits the clinical application of these agents. POU4F1 is a stem cell-associated transcription...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lin, Yue, Qiao, Ma, Jingjing, Liu, Yu, Zhao, Tao, Guo, Weinan, Zhu, Guannan, Guo, Sen, Wang, Shiyu, Gao, Tianwen, Li, Chunying, Shi, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293281/
https://www.ncbi.nlm.nih.gov/pubmed/32532957
http://dx.doi.org/10.1038/s41419-020-2662-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293281/
https://www.ncbi.nlm.nih.gov/pubmed/32532957
http://dx.doi.org/10.1038/s41419-020-2662-2

Ejemplares similares